AbbVie chases its next golden goose for a post-Humira future with new ulcerative colitis data for Rinvoq

Still bathing in the afterglow of its big-money acquisition of Allergan, AbbVie faces the dark cloud of a post-Humira future — and the deadline is approaching fast. Key to AbbVie’s plan are two immunology launches with aggressive clinical dreams; one of those, JAK inhibitor Rinvoq, is now one step closer to another Humira-matching approval.